Effects on Serum Uric Acid by Difference of the Renal Protective Effects with Atorvastatin and Rosuvastatin in Chronic Kidney Disease Patients

被引:13
作者
Kose, Eiji [1 ]
An, Taesong [3 ]
Kikkawa, Akihiko [3 ]
Matsumoto, Yoshiaki [2 ]
Hayashi, Hiroyuki [1 ]
机构
[1] Nihon Univ, Sch Pharm, Dept Pharmacotherapy, Funabashi, Chiba 2748555, Japan
[2] Nihon Univ, Sch Pharm, Dept Clin Pharmacokinet, Funabashi, Chiba 2748555, Japan
[3] Yokosuka Kyousai Hosp, Yokosuka, Kanagawa 2388588, Japan
关键词
chronic kidney disease (CKD) stages 3; hyperuricemia; hyperlipidemia; Atorvastatin; Rosuvastatin; CORONARY-HEART-DISEASE; URATE TRANSPORTER; FENOFIBRATE; HYPERURICEMIA; PROGRESSION; THERAPY; STATINS; PEOPLE; IMPACT; LEVEL;
D O I
10.1248/bpb.b13-00418
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyperuricemia and hyperlipidemia have attracted attention as progression factors for chronic kidney disease (CKD). In the drug treatment of hyperuricemia and hyperlipidemia complications, Atorvastatin (ATV), which inhibits urinary protein, increases glomerular filtration rate (GFR) and has renal protective effects, and Rosuvastatin (ROS) were found be suitable because they promote serum uric acid (SUA) excretion. However, these drugs were administered at very high doses in previous studies. In this study, we have investigated the effects of ATV or ROS on renal protective effects and their SUA levels before and three months after each drug administration in CKD patients. We retrospectively investigated outpatients presenting with CKD (stages 3) on the basis of their electronic medical records as subjects. Estimated GFR (eGFR) was significantly increased after ATV administration, whereas no change in eGFR was observed following ROS administration. Furthermore, SUA levels significantly decreased after ATV administration, whereas no changes were observed following ROS administration. Therefore, it may be not necessary to administer drugs that lower the SUA levels to patients presenting with hyperuricemia and hyperlipidemia complications associated with moderate renal failure, such as patients with at least stage 3 CKD. We consider that, by selecting ATV, the renal protective effects and SUA-lowering effect would be sufficient.
引用
收藏
页码:226 / 231
页数:6
相关论文
共 50 条
[41]   Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population [J].
Satirapoj, Bancha ;
Supasyndh, Ouppatham ;
Chaiprasert, Amnart ;
Ruangkanchanasetr, Prajej ;
Kanjanakul, Inseey ;
Phulsuksombuti, Duangporn ;
Utainam, Darunee ;
Choovichian, Panbuppa .
NEPHROLOGY, 2010, 15 (02) :253-258
[42]   Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community - The Hisayama Study [J].
Takae, Keita ;
Nagata, Masaharu ;
Hata, Jun ;
Mukai, Naoko ;
Hirakawa, Yoichiro ;
Yoshida, Daigo ;
Kishimoto, Hiro ;
Tsuruya, Kazuhiko ;
Kitazono, Takanari ;
Kiyohara, Yutaka ;
Ninomiya, Toshiharu .
CIRCULATION JOURNAL, 2016, 80 (08) :1857-+
[43]   Association between serum uric acid level and renal arteriolar hyalinization in individuals without chronic kidney disease [J].
Matsukuma, Yuta ;
Masutani, Kosuke ;
Tanaka, Shigeru ;
Tsuchimoto, Akihiro ;
Haruyama, Naoki ;
Okabe, Yasuhiro ;
Nakamura, Masafumi ;
Tsuruya, Kazuhiko ;
Kitazono, Takanari .
ATHEROSCLEROSIS, 2017, 266 :121-127
[44]   Association of Uric Acid and Left Ventricular Mass Index With Renal Outcomes in Chronic Kidney Disease [J].
Chen, Szu-Chia ;
Chang, Jer-Ming ;
Yeh, Shin-Meng ;
Su, Ho-Ming ;
Chen, Hung-Chun .
AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (02) :243-249
[45]   Renal effects of uric acid: hyperuricemia and hypouricemia [J].
Park, Jung Hwan ;
Jo, Yong-Il ;
Lee, Jong-Ho .
KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (06) :1291-1304
[46]   Effects of atorvastatin on oxidative stress in chronic kidney disease [J].
Fassett, Robert G. ;
Robertson, Iain K. ;
Ball, Madeleine J. ;
Geraghty, Dominic P. ;
Coombes, Jeff S. .
NEPHROLOGY, 2015, 20 (10) :697-705
[47]   Serum Uric Acid and Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis [J].
Zhang, Jialing ;
Lu, Xiangxue ;
Li, Han ;
Wang, Shixiang .
BLOOD PURIFICATION, 2021, 50 (06) :758-766
[48]   Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease [J].
Prezelin-Reydit, Mathilde ;
Combe, Christian ;
Fouque, Denis ;
Frimat, Luc ;
Jacquelinet, Christian ;
Laville, Maurice ;
Massy, Ziad ;
Lange, Celine ;
Ayav, Carole ;
Pecoits-Filho, Roberto ;
Liabeuf, Sophie ;
Stengel, Benedicte ;
Harambat, Jerome ;
Leffondre, Karen .
SCIENTIFIC REPORTS, 2023, 13 (01)
[49]   The Effects of Cardiometabolic Factors on the Association Between Serum Uric Acid and Chronic Kidney Disease in Chinese Middle-Aged and Older Population: A Mediation Analysis [J].
Xu, Lu ;
Sun, Hang ;
Liu, Lili ;
Zhan, Siyan ;
Wang, Shengfeng ;
Lv, Xiaozhen ;
Song, Yongfeng .
FRONTIERS IN ENDOCRINOLOGY, 2021, 12
[50]   Serum Uric Acid Level and Endothelial Dysfunction in Patients with Nondiabetic Chronic Kidney Disease [J].
Kanbay, Mehmet ;
Yilmaz, Mahmut Ilker ;
Sonmez, Alper ;
Turgut, Faruk ;
Saglam, Mutlu ;
Cakir, Erdinc ;
Yenicesu, Mujdat ;
Covic, Adrian ;
Jalal, Diana ;
Johnson, Richard J. .
AMERICAN JOURNAL OF NEPHROLOGY, 2011, 33 (04) :298-304